medigraphic.com
ISSN 0188-2198 (Print)

2002, Number 4

Next >>

Rev Mex Cardiol 2002; 13 (4)

Amiodarona: Side effects in 200 mexican patients for a two year period. Prospective study

Cadena-Sillas JA, Lepe-Montoya L

Language: Spanish
References: 21
Page: 149-152
PDF size: 65. Kb.


ABSTRACT

We studied the side effects of amiodarone administration for a two year period in 200 patients. Thyroid, lung & liver function test, cardiac, endocrinologic, neurologic, ophtamological & dermatological examination were done periodically. The average dose of amiodarone administration was 1,260 mg/week. After 2 years of therapy 6% of the patients developed thyroid dysfunction, 86% corneal microdeposit, and no pulmonary toxicity was detected. Only 9% of the patients stop the treatment because of intolerance. Conclusion: Amiodarone at dose of 1,260 mg/week during a 2 years administration period cause no pulmonary toxicity in mexican population.


REFERENCES

  1. Barsky AJ, Cleary PD, Barnett MC et al. The accuracy of symptom reporting by patient complaing palpitations. Am J Med 1994; 97: 214-221.

  2. Weinberg BA, Milles WM, Klein LS et al. Five year follow up of 589 patients treated with amiodarone. Am Heart J 1993; 125: 109.

  3. American Heart Association. Circulation 2000; 102: I-86.

  4. Reader EA, Podrid PJ, Lown B. Side effects and complications on amiodarone therapy. Am Heart J 1985; 55: 975-0.

  5. Greene HL, Graham EL, Werner JA et al. Toxic and therapy effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 1983; 2: 1114-9.

  6. Braunwald E. Heart disease. A textbook of cardiovascular medicine. Sixth edition. Philadelphia. Saunders Company 2001: 733-4.

  7. Hilleman D, Miller MA, Parker R et al. Optimal management of amiodarone therapy: efficacy and side effects Pharmacotherapy. 1998; 18: 188.

  8. Pritchard DA, Singh BN, Hurley FJ. Effects of Amiodarone therapy on thyroid function in patients with ischemic heart disease. Br Heart J 1975; 37: 856.

  9. Marchliniski FE, Gansler TS, Warman HL, Josephson ME. Amiodarone pulmonary toxicity. Ann Intern Med 1982; 97: 839.

  10. Sobol SM, Rakita L. Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. Circulation 1982; 65: 819.

  11. Bedrossian CW, Warren CJ, Ohar J et al. Amiodarone pulmonary toxicity: citopathology, ultrastructure and immunocytochemistry. Ann Diagn Pathol 1997; 1: 47.

  12. Mason JW. Amiodarone. N Engl J Med 1987; 316: 455.

  13. Colín LJL, Febles PT, Crespo MF y cols. Estudio retrospectivo para el análisis de los efectos colaterales de la amiodarona. Arch Inst Cardiol Mex 1990; 60: 455-60.

  14. Posadas RC, Olguín AR, Baltazares LE, Molina L, González L. Disfunción tiroidea inducida por amiodarona. Arch Inst Cardiol Mex 1985; 55: 399.

  15. BramhnSingh D, Nadamanee P. Amiodarone and thyroid function. Clinical implication during antiarrhythmic therapy. Am Heart J 1983; 106: 857-869.

  16. Borowski GD, Garofano CD, Rose LI et al. Effects of long term amiodarone therapy on thyroid hormone levels & thyroid function. Am J Med 1985; 8: 433.

  17. Mechlisa S, Lubine E, Laor J, Margaliot M, Stasberg B. Amiodarone-induced thyroid gland dysfunction. Am J Cardiol 1987; 59: 833.

  18. Lustman F, Monseau G. Amiodarone & neurological side effects. Lancet 1974; 1: 568.

  19. Fogoros RN, Anderson KP, Winckle RA, Swerdolw CD, Mason JW. Amiodarone clinical efficacy & toxicity in 96 patients with recurrent drug refractary arrhythmias.

  20. Ingram DV, Jaggarao NSV, Chamberlain DA. Ocular changes resulting from therapy with amiodarone. Br J Ophtalmol 1982; 66: 676.

  21. D’Amico DJ, Kenyon KR, Rushkin JN. Amiodarone keratopathy: drug induced lipid storage disease. Arch Ophthalmol 1981; 99: 257.




2020     |     www.medigraphic.com